6-substituted dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide compounds and their preparation and application

By developing a novel 6-position substituted 3,4-dihydrobenzo[e][1,2,3]oxazide 2,2-dioxide compound as a forward allosteric regulator of AMPA receptors, It solves the problems of neurotoxicity and functional instability caused by AMPA receptor agonists, realizes the regulation of BDNF expression and enhances neuronal function, and has the potential to treat neuropsychiatric diseases.

CN115232090BActive Publication Date: 2024-11-19HANGZHOU SEVENTH PEOPLES HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210849017.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-07-19
Publication Date
2024-11-19
Estimated Expiration
2042-07-19

AI Technical Summary

Technical Problem

Existing AMPA receptor agonists are prone to neurotoxicity, and their binding to receptors is unstable, leading to rapid functional inactivation, and unable to effectively regulate the expression of brain-derived neurotrophic factor BDNF, which in turn affects neuronal repair and synaptic plasticity. .

Method used

Develop a novel 6-position substituted 3,4-dihydrobenzo[e][1,2,3]oxazide 2,2-dioxide compound as a forward allosteric regulator of AMPA receptors, by Specific structures bind to AMPA receptors, stabilize the binding of agonists to receptors, reduce receptor inactivation rates, enhance receptor function, and are used to treat neuropsychiatric diseases.

Benefits of technology

This compound can stably regulate AMPA receptors, enhance their functions, promote neuronal calcium ion influx, significantly improve the expression of BDNF, and has potential effects in the treatment of diseases such as schizophrenia, Alzheimer's disease, Parkinson's disease, etc. , and non-toxic.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115232090B_ABST
    Figure CN115232090B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of organic synthesis medicine, and specifically relates to a 6-substituted 3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide compound, the general formula of which is as follows: #imgabs0# The 6-substituted 3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide compound can serve as a positive allosteric modulator of AMPA receptors, and it is confirmed that the compound can positively regulate AMPA receptors, and can make the conformation of agonists (such as endogenous neurotransmitter glutamate) after binding to the receptor more stable, thereby reducing the receptor inactivation rate and inhibiting receptor desensitization, so that the function of AMPA receptors can be enhanced.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of innovative chemical drug technology, and specifically refers to 6-substituted dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide compounds and preparation and application thereof. Background Art

[0002] AMPA receptors are ligand-gated ion channel glutamate receptors. When the endogenous agonist glutamate binds to the ligand binding domain (LBD), it causes a conformational change, the nerve cell ion channel opens, and Na + Continuous influx of magnesium into the cell leads to depolarization of the posterior membrane and generation of an action potential, which eliminates the resting Mg 2+ Blockade of NMDA receptor channels, at which time Ca 2+ It can enter cells through NMDA receptors, trigger excitatory postsynaptic currents (EPSCs), and mediate fast excitatory synaptic transmission.

[0003] AMPA receptor positive modulators and AMPA receptor agonists have different binding sites, which can make the conformation of agonists (such as endogenous neurotransmitter glutamate) after binding to receptors more stable, thereby reducing the receptor inactivation rate and inhibiting receptor desensitization, so that the function of AMPA receptors can be enhanced. Compared with agonists that act directly on AMPA receptors, positive modulators have more advantages, because agonists directly bind to the binding sites of receptors, which can easily over-stimulate the receptors, induce neurotoxicity, and cause uncontrollable damage to the brain; positive modulators will not have such over-stimulation, so they will not cause neurotoxic damage.

[0004] Studies have shown that AMPA receptor positive modulators can regulate the expression of brain-derived neurotrophic factor (BDNF). Increased BDNF expression promotes neuronal repair, axonal regeneration, regulation of synaptic plasticity, neurotransmitter transmission and other nervous system functions. At the same time, AMPA receptor positive modulators specifically bind to receptors to produce the effect of positively regulating agonists, promote the inward current of single cells or facilitate synaptic transmission between neurons. It has been proven in a variety of animal models and clinical studies that it can be used as a drug target and has broad development prospects. Summary of the invention

[0005] The purpose of the present invention is to provide a 6-substituted 3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide compound with novel structure and strong activity.

[0006] Another object of the present invention is to provide a specific preparation method of the above-mentioned 6-substituted 3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide compounds.

[0007] Another object of the present invention is to provide a specific application of the above-mentioned 6-substituted 3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide compounds as positive allosteric modulators of AMPA receptors.

[0008] The last object of the present invention is to use the positive allosteric modulator of AMPA receptor provided above for preparing drugs for treating neuropsychiatric diseases.

[0009] The present invention provides a 6-substituted 3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide compound, the general formula of which is as follows:

[0010]

[0011] in,

[0012] A is an independent benzene ring, pyridine ring, indazole ring, indole ring, isoindole ring,

[0013] R1 is independently a methyl group, a methoxy group, or a halogen atom;

[0014] R2 and R3 are independently H, methyl, halogen, tert-butyl, cyano, F3C-, phenyl, vinyl, dimethylamino, amino, sulfonic acid, naphthyl, 4-morpholinyl, Isobutyl Diethylamino, Hydrogen atoms may not exist;

[0015] R4 is independently methyl, isopropyl, phenyl, benzyl, F3C-, tert-butyl, ethyl, n-propyl, Isobutyl

[0016] R5 is independently methoxy, methyl, ethoxy, Phenyl, 4-morpholinyl,

[0017] R6 and R7 are independently a hydrogen atom, a methyl group, an isopropyl group or an ethyl group.

[0018] The specific compounds it contains are as follows:

[0019]

[0020]

[0021]

[0022]

[0023]

[0024]

[0025] Its synthetic route is as follows:

[0026]

[0027] The specific preparation method comprises the following steps:

[0028] (1) Dissolving the raw material A in acetic acid solvent at room temperature, then adding liquid bromine dropwise, stirring the mixture at room temperature until the reaction is complete, adding water to precipitate solids after the reaction is complete, filtering and washing the filter cakes with water to obtain intermediate I;

[0029] (2) At 0°C, intermediate I was dispersed in 60 ml of dimethylacetamide (DMA), and then aminosulfonyl chloride was quickly added under nitrogen protection. The reaction system was stirred and slowly warmed to room temperature until the reaction was complete. After the reaction was complete, water was added to precipitate solids, which were filtered and the filter cake was washed with water and ethyl acetate, respectively, to obtain intermediate II;

[0030] (3) Disperse Intermediate II in MeOH solvent system, add sodium borohydride in batches at room temperature, continue stirring at room temperature after addition until Intermediate II reacts completely, quench with saturated ammonium chloride solution (20 ml), transfer to a separatory funnel with 30 mL of ethyl acetate, separate the organic layer, and extract the aqueous layer with ethyl acetate. The combined organic layer is washed with H2O and saturated NaCl aqueous solution in turn, dried over Na2SO4, and concentrated under reduced pressure, and purified by silica gel chromatography to obtain Intermediate III;

[0031] (4) The intermediate III, raw material B, potassium carbonate, Pd(dppf)Cl2, dioxane and H2O were added to a 25 ml two-necked bottle in sequence, and stirred at 80°C for 10 h under argon protection. After the reaction was completed by TLC, 20 ml of saturated brine was added, and the mixture was extracted twice with ethyl acetate. The organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain the target product.

[0032] The present invention also provides a positive allosteric modulator of AMPA receptor, which is a biopharmaceutically acceptable salt with the above-mentioned 6-substituted 3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide compound as the main active ingredient.

[0033] The present invention also provides a drug for treating neuropsychiatric diseases, which is a pharmaceutical composition prepared by using the above-mentioned positive allosteric modulator of AMPA receptor as the main component and adding pharmaceutically acceptable, non-toxic and non-inert pharmaceutical carriers and / or excipient auxiliary components to humans and animals.

[0034] The pharmaceutical carrier or excipient is one or more solid, semi-solid and liquid diluents, fillers and pharmaceutical product adjuvants.

[0035] The pharmaceutical composition is prepared into various dosage forms using methods recognized in the pharmaceutical and food fields: spray, aerosol, liquid preparation or solid preparation; the liquid preparation includes injection, suspension, emulsion, solution or syrup; the solid preparation includes tablets, capsules, granules or granules.

[0036] The neuropsychiatric diseases treated by the drug include schizophrenia, Alzheimer's disease, Parkinson's disease, depression, and bipolar disorder.

[0037] The administration route of the drug is oral administration, sublingual administration or mucosal dialysis; the injection includes intravenous injection, intravenous drip, intramuscular injection, intraperitoneal injection or subcutaneous injection.

[0038] Compared with the prior art, the present invention has the following advantages and beneficial effects:

[0039] The present invention synthesizes a novel compound, which can serve as a positive allosteric modulator of AMPA receptors. It is confirmed that the compound can positively regulate AMPA receptors and can make the conformation of agonists (such as endogenous neurotransmitter glutamate) after binding to the receptors more stable, thereby reducing the receptor inactivation rate and inhibiting receptor desensitization, so that the function of AMPA receptors can be enhanced. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] Figure 1 The compound LT-261 in the present invention is calcium influx EC 50 Test result graph;

[0041] Figure 2 The compound LT-285 of the present invention is calcium influx EC 50 Test result graph;

[0042] Figure 3 The compound LT-286 calcium influx EC of the present invention 50 Test result graph;

[0043] Figure 4 The compound LT-287 in the present invention is calcium influx EC 50 Test result graph;

[0044] Figure 5 The compound LT-290 calcium influx EC of the present invention 50 Test result graph. DETAILED DESCRIPTION

[0045] The present invention is further described in detail below in conjunction with embodiments, but the embodiments of the present invention are not limited thereto. Without departing from the above-mentioned technical concept of the present invention, various substitutions and changes are made according to common technical knowledge and customary means in the field, which should all be included in the scope of the present invention.

[0046] In order to make the purpose, process conditions and advantages of the present invention more clearly understood, the present invention is further described in detail in conjunction with the following implementation examples. The specific implementation examples described herein are only used to explain the present invention and are not used to limit the present invention.

[0047] Embodiment 1:

[0048] The compound disclosed in this example: 8-(4-methylphenyl)-6-methyl-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-200)

[0049]

[0050] The specific synthetic route is as follows:

[0051]

[0052] The specific preparation method is as follows:

[0053] (1) Under room temperature, 2-hydroxy-5-methylbenzaldehyde A1 (10.0 g, 74.0 mmol) was dissolved in 100 ml of acetic acid solvent, and then liquid bromine (4.2 mL, 80.0 mmol) was added dropwise, and the mixture was stirred at room temperature until the reaction was complete. After the reaction was completed, water was added to precipitate the solid, which was filtered and the filter cake was washed with water to obtain 3-bromo-2-hydroxy-5-methylbenzaldehyde B1 (11.9 g) with a yield of 75%;

[0054] (2) At 0°C, 3-bromo-2-hydroxy-5-methylbenzaldehyde B1 (A01a) (6.0 g, 28 mmol) was dispersed in 60 ml of dimethylacetamide DMA, and then aminosulfonyl chloride (10 g, 86.5 mmol) was quickly added under nitrogen protection. The reaction system was stirred and slowly warmed to room temperature until the reaction was complete. After the reaction was completed, water was added to precipitate the solid, which was filtered and the filter cake was washed with water and ethyl acetate respectively to obtain 8-bromo-6-methylbenzo[e][1,2,3]thiazine 2,2-dioxide C1 (6.18 g) with a yield of 80%;

[0055] (3) Then C1 (2.76 g, 10 mmol) was dispersed in 50 ml MeOH solvent system, and sodium borohydride (380 mg, 10.6 mmol) was added in batches at room temperature. After the addition, stirring was continued at room temperature until the raw material C1 was completely reacted. It was quenched with saturated ammonium chloride solution (20 ml) and transferred to a separatory funnel with 30 mL ethyl acetate. The organic layer was separated and the aqueous layer was extracted with 2×30 mL ethyl acetate. The combined organic layer was washed with 2×20 mL H2O and 1×20 mL saturated NaCl aqueous solution in turn, dried over Na2SO4, and concentrated under reduced pressure. It was purified by silica gel chromatography to obtain the intermediate 8-bromo-6-methyl-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide D1 (2.22 g) with a yield of 80%;

[0056] (4) Compound D1 (55 mg, 0.2 mmol), 4-tolueneboronic acid F1 (33 mg, 0.24 mmol), potassium carbonate (56 mg, 0.4 mmol), Pd(dppf)Cl2 (14 mg, 0.02 mmol), dioxane (4 ml), and H2O (1 ml) were added to a 25 ml two-necked bottle in sequence and stirred at 80°C for 10 h under argon protection. After TLC detection, saturated brine (20 ml) was added, and the mixture was extracted twice with ethyl acetate (20 ml). The organic phases were combined, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain the target product LT-200 with a yield of 90%.

[0057] That 1 The H NMR data are as follows:

[0058] 1 H NMR (500MHz, DMSO-d6) δ8.51(s,1H),7.53–7.45(m,2H),7.45–7.37(m,3H),7.19(d,J=2.2Hz,1H),7.12(d,J=2.2Hz,1H),4.57(s,2H),2.32(s,3H).

[0059] Embodiment 2:

[0060] The compound disclosed in this example: 6-methyl-8-phenyl-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-201)

[0061]

[0062] The synthetic route is the same as in Example 1, except that "4-tolueneboric acid" in step (4) is replaced by "phenylboric acid".

[0063] That 1 The H NMR data are as follows:

[0064] 1 H NMR (500MHz, DMSO-d6) δ8.51(s,1H),7.53–7.45(m,2H),7.45–7.37(m,3H),7.19(d,J=2.2Hz,1H),7.12(d,J=2.2Hz,1H),4.57(s,2H),2.32(s,3H).

[0065] Embodiment 3:

[0066] The compound disclosed in this example: 8-(4-methoxyphenyl)-6-methyl-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-202)

[0067]

[0068] The synthetic route is the same as in Example 1, except that "4-toluene boronic acid" in step (4) is replaced by "4-methoxyphenylboronic acid".

[0069] That 1 The H NMR data are as follows:

[0070] 1 H NMR(500MHz,DMSO-d6)δ8.47(s,1H),7.36(d,J=8.7Hz,2H),7.16(d,J=2.2Hz,1H) ,7.07(d,J=2.1Hz,1H),7.05–7.02(m,2H),4.56(s,2H),3.80(s,3H),2.31(s,3H).

[0071] Embodiment 4:

[0072] The compound disclosed in this example: 8-(4-fluorophenyl)-6-methyl-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-203)

[0073]

[0074] The synthetic route is the same as in Example 1, except that "4-tolueneboric acid" in step (4) is replaced by "4-fluorophenylboric acid".

[0075] That 1 The H NMR data are as follows:

[0076] 1H NMR (500MHz, DMSO-d6) δ8.51(s,1H),7.47–7.41(m,2H),7.35–7.27(m,2H),7.18(d,J=2.2Hz,1H),7.11(d,J=2.1Hz,1H),4.56(s,2H),2.31(s,3H).

[0077] Embodiment 5:

[0078] The compound disclosed in this example: 8-(4-isopropoxyphenyl)-6-methyl-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-204)

[0079]

[0080] The synthetic route is the same as in Example 1, except that "4-toluene boronic acid" in step (4) is replaced by "4-isopropoxyphenylboronic acid".

[0081] That 1 The H NMR data are as follows:

[0082] 1 H NMR (500MHz, DMSO-d6) δ8.46(s,1H),7.32(d,J=8.7Hz,2H),7.14(d,J=2.2Hz,1H),7.05(d,J=2.1Hz,1 H),6.99(d,J=8.8Hz,2H),4.65(hept,J=6.0Hz,1H),4.54(s,2H),2.29(s,3H),1.28(d,J=6.0Hz,6H).

[0083] Embodiment 6:

[0084] The compound disclosed in this example: 8-(4-tert-butylphenyl)-6-methyl-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-205)

[0085]

[0086] The synthetic route is the same as in Example 1, except that the "4-toluene boronic acid" in step (4) is replaced by "4-tert-butylphenyl boronic acid".

[0087] That 1 The H NMR data are as follows:

[0088] 1H NMR(500MHz,DMSO-d6)δ8.50(s,1H),7.50(d,J=8.5Hz,2H),7.36(d,J=8.4Hz,2H),7 .18(d,J=2.2Hz,1H),7.09(d,J=2.1Hz,1H),4.57(s,2H),2.31(s,3H),1.33(s,9H).

[0089] Embodiment 7:

[0090] The compound disclosed in this example: 8-(4-trifluoromethylphenyl)-6-methyl-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-206)

[0091]

[0092] The synthetic route is the same as in Example 1, except that "4-tolueneboronic acid" in step (4) is replaced by "4-trifluoromethylphenylboronic acid".

[0093] That 1 The H NMR data are as follows:

[0094] 1 H NMR(500MHz,DMSO-d6)δ8.58(s,1H),7.86(d,J=8.1Hz,2H),7.65(d,J=8.1Hz ,2H),7.26(d,J=2.1Hz,1H),7.19(d,J=2.1Hz,1H),4.60(s,2H),2.34(s,3H).

[0095] Embodiment 8:

[0096] The compound disclosed in this example: methyl 4-(6-methyl-2,2-dihydroxy-3,4-dihydrobenzo[e][1,2,3]oxathiazin-8-yl)benzoate (LT-207)

[0097]

[0098] The synthetic route is the same as in Example 1, except that "4-toluene boronic acid" in step (4) is replaced by "4-methoxycarbonylphenylboronic acid".

[0099] That 1 The H NMR data are as follows:

[0100] 1H NMR(500MHz,DMSO-d6)δ8.47(s,1H),7.36(d,J=8.7Hz,2H),7.16(d,J=2.2Hz,1H) ,7.07(d,J=2.1Hz,1H),7.05–7.02(m,2H),4.56(s,2H),3.80(s,3H),2.31(s,3H).

[0101] Embodiment 9:

[0102] The compound disclosed in this example: 8-(4-cyanophenyl)-6-methyl-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (LT-208)

[0103]

[0104] The synthetic route is the same as in Example 1, except that "4-tolueneboronic acid" in step (4) is replaced by "4-cyanophenylboronic acid".

[0105] That 1 The H NMR data are as follows:

[0106] 1 H NMR (500MHz, DMSO-d6) δ7.96(d,J=8.4Hz,2H),7.62(d,J=8.4Hz,2H),7.25(d,J=2.4Hz,1H),7.19(d,J=2.4Hz,1H),4.59(s,2H),2.33(s,3H).

[0107] Embodiment 10:

[0108] The compound disclosed in this example: 8-([1,1'-biphenyl]-4-yl)-6-methyl-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-209)

[0109]

[0110] The synthetic route is the same as in Example 1, except that "4-toluene boronic acid" in step (4) is replaced by "4-biphenyl boronic acid".

[0111] That 1 The H NMR data are as follows:

[0112] 1H NMR(500MHz,DMSO-d6)δ8.54(s,1H),7.78(d,J=7.9Hz,2H),7.74(d,J=7.7Hz,2H),7.56– 7.46(m,4H),7.40(t,J=7.4Hz,1H),7.25(s,1H),7.13(s,1H),4.60(s,2H),2.34(s,3H).

[0113] Embodiment 11:

[0114] The compound disclosed in this example: 8-(4-phenoxyphenyl)-6-methyl-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-210)

[0115]

[0116] The synthetic route is the same as in Example 1, except that "4-tolueneboronic acid" in step (4) is replaced by "4-phenoxyphenylboronic acid".

[0117] That 1 The H NMR data are as follows:

[0118] 1 H NMR (500MHz, DMSO-d6) δ8.51(s,1H),7.49–7.39(m,4H),7.24–7.15(m,2H),7.13–7.06(m,5H),4.57(s,2H),2.32(s,3H).

[0119] Embodiment 12:

[0120] The compound disclosed in this example: 8-(4-methylphenyl)-6-methyl-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-211)

[0121]

[0122] The synthetic route is the same as that of Example 1, except that the "2-hydroxy-5-methylbenzaldehyde" in step (1) is replaced by "2-hydroxy-5-methoxybenzaldehyde".

[0123] That 1 The H NMR data are as follows:

[0124] 1 H NMR (500MHz, DMSO-d6) δ7.32(d,J=7.8Hz,2H),7.27(d,J=7.9Hz,2H),6.86(s,2H),4.54(s,2H),3.76(s,3H),2.34(s,3H).

[0125] Embodiment 13:

[0126] The compound disclosed in this example: 8-(4-fluorophenyl)-6-methyl-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-212)

[0127]

[0128] The synthetic route is the same as that of Example 12, except that "4-tolueneboric acid" in step (4) is replaced by "4-fluorophenylboric acid".

[0129] That 1 The H NMR data are as follows:

[0130] 1 H NMR (500MHz, DMSO-d6) δ7.47(dd,J=8.6,5.6Hz,2H),7.31(t,J=8.9Hz,2H),6.89(s,2H),4.55(s,2H),3.77(s,3H).

[0131] Embodiment 14:

[0132] The compound disclosed in this example: 8-(4-isopropoxyphenyl)-6-methyl-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-213)

[0133]

[0134] The synthetic route is the same as in Example 12, except that "4-toluene boronic acid" in step (4) is replaced by "4-isopropoxyphenylboronic acid".

[0135] That 1 The H NMR data are as follows:

[0136] 1 H NMR (500MHz, DMSO-d6) δ7.34(d,J=8.8Hz,2H),6.99(d,J=8.8Hz,2H),6.84(d,J=3.1Hz,1H),6. 83(d,J=3.1Hz,1H),4.65(hept,J=6.0Hz,1H),4.53(s,2H),3.76(s,3H),1.28(d,J=6.0Hz,6H).

[0137] Embodiment 15:

[0138] The compound disclosed in this example: 8-(4-tert-butylphenyl)-6-methyl-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-214)

[0139]

[0140] The synthetic route is the same as in Example 12, except that "4-tolueneboronic acid" in step (4) is replaced by "4-tert-butylphenylboronic acid".

[0141] That 1 The H NMR data are as follows:

[0142] 1 H NMR(500MHz,DMSO-d6)δ7.49(d,J=8.4Hz,2H),7.37(d,J=8.4Hz,2H),6.88(d ,J=3.1Hz,1H),6.87(d,J=3.2Hz,1H),4.55(s,2H),3.77(s,3H),1.31(s,9H).

[0143] Embodiment 16:

[0144] The compound disclosed in this example: 8-(4-trifluoromethylphenyl)-6-methyl-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-215)

[0145]

[0146] The synthetic route is the same as that of Example 12, except that "4-tolueneboronic acid" in step (4) is replaced by "4-trifluoromethylphenylboronic acid".

[0147] That 1 The H NMR data are as follows:

[0148] 1 H NMR (500MHz, DMSO-d6) δ7.84(d,J=8.0Hz,2H),7.65(d,J=7.9Hz,2H),6.97(d,J=3.2Hz,1H),6.95(d,J=3.2Hz,1H),4.58(s,2H),3.78(s,3H).

[0149] Embodiment 17:

[0150] The compound disclosed in this example: methyl 4-(6-methoxy-2,2-dihydroxy-3,4-dihydrobenzo[e][1,2,3]oxathiazin-8-yl)benzoate (LT-216)

[0151]

[0152] The synthetic route is the same as that in Example 12, except that "4-toluene boronic acid" in step (4) is replaced by "4-methoxycarbonylphenylboronic acid".

[0153] That 1 The H NMR data are as follows:

[0154] 1 H NMR (500MHz, DMSO-d6) δ8.04(d,J=8.1Hz,2H),7.58(d,J=8.2Hz,2H),6.93(s,2H),4.56(s,2H),3.87(s,3H),3.78(s,3H).

[0155] 13C NMR (126MHz, DMSO-d6) δ166.44,155.89,142.48,140.71,130.96,130.09,129.67,129.43,121.77,115.64,112.30,56.19,52.72,46.19.

[0156] Embodiment 18:

[0157] The compound disclosed in this example: 8-([1,1'-biphenyl]-4-yl)-6-methoxy-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (LT-217)

[0158]

[0159] The synthetic route is the same as that of Example 12, except that "4-toluene boronic acid" in step (4) is replaced by "4-biphenyl boronic acid".

[0160] That 1 The H NMR data are as follows:

[0161] 1 H NMR (600MHz, DMSO-d6) δ8.49(s,1H),7.76(d,J=8.3Hz,2H),7.71(d,J=6.9Hz,2H),7.52(d,J=8.3Hz,2H),7.47( t,J=7.7Hz,2H),7.37(t,J=7.4Hz,1H),6.94(d,J=3.0Hz,1H),6.90(d,J=3.0Hz,1H),4.57(s,2H),3.78(s,3H).

[0162] Embodiment 19:

[0163] The compound disclosed in this example: 8-(4-phenoxyphenyl)-6-methoxy-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (LT-218)

[0164]

[0165] The synthetic route is the same as Example 12, except that "4-tolueneboronic acid" in step (4) is replaced by "4-phenoxyphenylboronic acid".

[0166] That 1 The H NMR data are as follows:

[0167] 1 H NMR(600MHz,DMSO-d6)δ8.46(s,1H),7.46–7.35(m,4H),7.16(t,J=7.4Hz,1H),7.10– 7.02(m,4H),6.88(d,J=3.1Hz,1H),6.87(d,J=3.1Hz,1H),4.54(s,2H),3.76(s,3H).

[0168] Embodiment 20:

[0169] The compound disclosed in this example: 6-fluoro-8-(4-methylphenyl)-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-219)

[0170]

[0171] The synthetic route is the same as in Example 1, except that the "2-hydroxy-5-methylbenzaldehyde" in step (1) is replaced by "5-fluoro-2-hydroxybenzaldehyde".

[0172] That 1 The H NMR data are as follows:

[0173] 1 H NMR(500MHz,DMSO-d6)δ8.59(s,1H),7.35(d,J=8.2Hz,2H),7.30(d,J=8.0Hz,2H), 7.25(dd,J=9.0,3.2Hz,1H),7.22(dd,J=8.4,3.1Hz,1H),4.62(s,2H),2.36(s,3H).

[0174] Embodiment 21:

[0175] The compound disclosed in this example: 6-fluoro-8-phenyl-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-220)

[0176]

[0177] The synthetic route is the same as in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "phenylboronic acid".

[0178] That 1 The H NMR data are as follows:

[0179] 1 H NMR (500MHz, DMSO-d6) δ8.62(s,1H),7.54–7.48(m,2H),7.47–7.41(m,3H),7.29(dd,J=9.1,3.2Hz,1H),7.25(dd,J=8.4,3.2Hz,1H),4.63(s,2H).

[0180] Embodiment 22:

[0181] The compound disclosed in this example: 6-fluoro-8-(4-methoxyphenyl)-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-221)

[0182]

[0183] The synthetic route is the same as in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-methoxyboronic acid".

[0184] That 1 The H NMR data are as follows:

[0185] 1 H NMR(500MHz,DMSO-d6)δ8.59(s,1H),7.45–7.37(m,2H),7.25(dd,J=9.1,3.1Hz ,1H),7.19(dd,J=8.4,3.1Hz,1H),7.09–7.03(m,2H),4.61(s,2H),3.81(s,3H).

[0186] Embodiment 23:

[0187] The compound disclosed in this example: 6-fluoro-8-(4-fluorophenyl)-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-222)

[0188]

[0189] The synthetic route is the same as that in Example 20, except that "4-tolueneboric acid" in step (4) is replaced by "4-fluorophenylboric acid".

[0190] That 1The H NMR data are as follows:

[0191] 1 H NMR (500MHz, DMSO-d6) δ8.63 (s, 1H), 7.51 (dd, J = 8.8, 5.5Hz, 2H), 7.35 (t, J = 8. 9Hz, 2H), 7.31 (dd, J=9.0, 3.2Hz, 1H), 7.25 (dd, J=8.5, 3.1Hz, 1H), 4.63 (s, 2H).

[0192] Embodiment 24:

[0193] The compound disclosed in this example: 6-fluoro-8-(4-isopropoxyphenyl)-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-223)

[0194]

[0195] The synthetic route is the same as in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-isopropoxyphenylboronic acid".

[0196] That 1 The H NMR data are as follows:

[0197] 1 H NMR (500MHz, DMSO-d6) δ8.57(s,1H),7.37(d,J=8.7Hz,2H),7.23(dd,J=9.1,3.1Hz,1H),7.17(dd,J =8.5, 3.1Hz, 1H), 7.01 (d, J = 8.7Hz, 2H), 4.67 (p, J = 6.0Hz, 1H), 4.60 (s, 2H), 1.28 (d, J = 6.0Hz, 6H).

[0198] Embodiment 25:

[0199] The compound disclosed in this example: 6-fluoro-8-(4-tert-butylphenyl)-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-224)

[0200]

[0201] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-tert-butylphenylboronic acid".

[0202] That 1 The H NMR data are as follows:

[0203] 1H NMR(500MHz,DMSO-d6)δ8.62(s,1H),7.52(d,J=8.5Hz,2H),7.40(d,J=8.3Hz,2H), 7.28(dd,J=9.0,3.1Hz,1H),7.22(dd,J=8.5,3.1Hz,1H),4.62(s,2H),1.33(s,9H).

[0204] Embodiment 26:

[0205] The compound disclosed in this example: 6-fluoro-8-(4-trifluoromethylphenyl)-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-225)

[0206]

[0207] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-trifluoromethylphenylboronic acid".

[0208] That 1 The H NMR data are as follows:

[0209] 1 H NMR (500MHz, DMSO-d6) δ8.69(s,1H),7.89(d,J=8.2Hz,2H),7.69(d,J=8.1Hz,2H),7.39(dd,J=8.8,3.1Hz,1H),7.33(dd,J=8.4,3.1Hz,1H),4.66(s,2H).

[0210] Embodiment 27:

[0211] The compound disclosed in this example: methyl 4-(6-fluoro-2,2-dihydroxy-3,4-dihydrobenzo[e][1,2,3]oxathiazin-8-yl)benzoate (LT-226)

[0212]

[0213] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-methoxycarbonylphenylboronic acid".

[0214] That 1 The H NMR data are as follows:

[0215] 1H NMR (500MHz, DMSO-d6) δ8.05(d,J=8.3Hz,2H),7.60(d,J=8.3Hz,2H),7.34(dd,J=8.9,3.1Hz,1H),7.28(dd,J=8.4,3.1Hz,1H),4.62(s,2H),3.88(s,3H).

[0216] Embodiment 28:

[0217] The compound disclosed in this example: 6-fluoro-8-(4-cyanophenyl)-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (LT-227)

[0218]

[0219] The synthetic route is the same as in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-cyanophenylboronic acid".

[0220] That 1 The H NMR data are as follows:

[0221] 1 H NMR (500MHz, DMSO-d6) δ7.97(d,J=8.4Hz,2H),7.65(d,J=8.4Hz,2H),7.37(dd,J=8.8,3.1Hz,1H),7.31(dd,J=8.5,3.1Hz,1H),4.63(s,2H).

[0222] Embodiment 29:

[0223] The compound disclosed in this example: 8-([1,1'-biphenyl]-4-yl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-228)

[0224]

[0225] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-biphenylboronic acid".

[0226] That 1 The H NMR data are as follows:

[0227] 1H NMR (600MHz, DMSO-d6) δ7.76(d,J=8.0Hz,2H),7.71(d,J=7.6Hz,2H),7.53(d,J=8.0Hz,2H),7.46(t,J=7 .6Hz,2H),7.37(t,J=7.4Hz,1H),7.29(dd,J=8.9,3.1Hz,1H),7.22(dd,J=8.5,3.1Hz,1H),4.60(s,2H).

[0228] Embodiment 30:

[0229] The compound disclosed in this example: 6-fluoro-8-(4-phenoxyphenyl)-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-229)

[0230]

[0231] The synthetic route is the same as in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-phenoxyphenylboronic acid".

[0232] That 1 The H NMR data are as follows:

[0233] 1 H NMR(500MHz,DMSO-d6)δ7.48–7.45(m,2H),7.42(dd,J=8.6,7.3Hz,2H),7.25(dd,J =9.0,3.1Hz,1H),7.22–7.16(m,2H),7.09(td,J=7.6,7.0,1.7Hz,4H),4.59(s,2H).

[0234] Embodiment 31:

[0235] The compound disclosed in this example: 8-(3,4-dimethoxyphenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-230)

[0236]

[0237] The synthetic route is the same as in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "3,4-dimethoxyphenylboronic acid".

[0238] That 1 The H NMR data are as follows:

[0239] 1H NMR(500MHz,DMSO-d6)δ8.59(s,1H),7.30(dd,J=9.1,3.1Hz,1H),7.18(dd,J=8.4,3.1H z,1H),7.06(d,J=8.4Hz,1H),7.04–6.98(m,2H),4.59(s,2H),3.80(s,3H),3.78(s,3H).

[0240] Embodiment 32:

[0241] The compound disclosed in this example: 8-(2,4-dimethoxyphenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-231)

[0242]

[0243] The synthetic route is the same as in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "2,4-dimethoxyphenylboronic acid".

[0244] That 1 The H NMR data are as follows:

[0245] 1 H NMR(500MHz,DMSO-d6)δ8.44(t,J=7.3Hz,1H),7.15(dd,J=8.5,3.1Hz,1H),7.11–6.97(m,2H),6. 66(d,J=2.4Hz,1H),6.61(dd,J=8.4,2.4Hz,1H),4.57(d,J=7.2Hz,2H),3.80(s,3H),3.72(s,3H).

[0246] Embodiment 33:

[0247] The compound disclosed in this example: 8-(Benzo[d][1,3]dioxol-5-yl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-232)

[0248]

[0249] The synthetic route is the same as in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "3,4-methylenedioxyphenylboronic acid".

[0250] That 1 The H NMR data are as follows:

[0251] 1H NMR (500MHz, DMSO-d6) δ8.59(s,1H),7.24(dd,J=9.0,3.1Hz,1H),7.19(dd,J=8.4,3.1Hz,1H),7. 03(d,J=8.0Hz,1H),6.98(d,J=1.8Hz,1H),6.93(dd,J=8.0,1.8Hz,1H),6.08(s,2H),4.59(s,2H).

[0252] Embodiment 34:

[0253] The compound disclosed in this example: 8-(3,5-difluorophenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-233)

[0254]

[0255] The synthetic route is the same as in Example 20, except that "4-tolueneboric acid" in step (4) is replaced by "3,5-difluorophenylboric acid".

[0256] That 1 The H NMR data are as follows:

[0257] 1 H NMR (500MHz, DMSO-d6) δ8.69 (s, 1H), 7.40 (dd, J=8.9, 3.1Hz, 1H), 7.36 (tt, J= 9.4, 2.4Hz, 1H), 7.31 (dd, J = 8.4, 3.1Hz, 1H), 7.23–7.14 (m, 2H), 4.63 (s, 2H).

[0258] Embodiment 35:

[0259] The compound disclosed in this example: 8-(4-benzyloxyphenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-234)

[0260]

[0261] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-benzyloxyphenylboronic acid".

[0262] That 1 The H NMR data are as follows:

[0263] 1H NMR(500MHz,DMSO-d6)δ8.58(s,1H),7.46(d,J=6.9Hz,2H),7.43–7.37(m,4H),7.37–7.27(m,1H),7.2 4(dd,J=9.1,3.1Hz,1H),7.18(dd,J=8.4,3.1Hz,1H),7.12(d,J=8.7Hz,2H),5.16(s,2H),4.60(s,2H).

[0264] Embodiment 36:

[0265] The compound disclosed in this example: 8-(4-chloro-3-fluorophenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-235)

[0266]

[0267] The synthetic route is the same as that in Example 20, except that "4-tolueneboric acid" in step (4) is replaced by "4-chloro-3-fluorophenylboric acid".

[0268] That 1 The H NMR data are as follows:

[0269] 1 H NMR(500MHz,DMSO-d6)δ8.70(s,1H),7.75(t,J=8.2Hz,1H),7.53(dd,J=10.4,2.0Hz,1H), 7.40(dd,J=8.9,3.1Hz,1H),7.37–7.33(m,1H),7.31(dd,J=8.4,3.2Hz,1H),4.65(s,2H).

[0270] Embodiment 37:

[0271] The compound disclosed in this example: 8-(2-fluoro-4-methylphenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-236)

[0272]

[0273] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "2-fluoro-4-methylphenylboronic acid".

[0274] That 1 The H NMR data are as follows:

[0275] 1H NMR (500MHz, DMSO-d6) δ8.58(s,1H),7.32–7.22(m,3H),7.16(d,J=11.3Hz,1H),7.12(dd,J=7.8,1.6Hz,1H),4.61(s,2H),2.37(s,3H).

[0276] Embodiment 38:

[0277] The compound disclosed in this example: 8-(2,3-difluorophenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (LT-237)

[0278]

[0279] The synthetic route is the same as that in Example 20, except that "4-tolueneboric acid" in step (4) is replaced by "2,3-difluorophenylboric acid".

[0280] That 1 The H NMR data are as follows:

[0281] 1 H NMR (500MHz, DMSO-d6) δ8.65(s,1H),7.54(dtd,J=10.1,8.1,1.6Hz,1H),7.40–7.30(m,3H),7.25–7.18(m,1H),4.63(s,2H).

[0282] Embodiment 39:

[0283] The compound disclosed in this example: 8-(4-chloro-2-fluorophenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-238)

[0284]

[0285] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-chloro-2-fluorophenylboronic acid".

[0286] That 1 The H NMR data are as follows:

[0287] That 1 The H NMR data are as follows:

[0288] 1 H NMR (500MHz, DMSO-d6) δ8.63(s,1H),7.68–7.57(m,1H),7.46–7.38(m,2H),7.32(d,J=8.5Hz,2H),4.62(s,2H).

[0289] Embodiment 40:

[0290] The compound disclosed in this example: 6-fluoro-8-(3-fluoro-[1,1'-biphenyl]-4-yl)-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-239)

[0291]

[0292] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "3-fluoro-4-biphenylboronic acid".

[0293] That 1 The H NMR data are as follows:

[0294] 1 H NMR (500MHz, DMSO-d6) δ8.69 (s, 1H), 7.66 (t, J = 8.3Hz, 1H), 7.62–7.58 (m, 2H), 7. 50(t,J=7.6Hz,2H),7.46–7.36(m,4H),7.29(dd,J=8.5,3.2Hz,1H),4.64(s,2H).

[0295] Embodiment 41:

[0296] The compound disclosed in this example: 1-(4-(6-fluoro-2,2-dihydroxy-3,4-dihydrobenzo[e][1,2,3]oxathiazin-8-yl)phenyl)ethan-1-one (LT-240)

[0297]

[0298] The synthetic route is the same as in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-acetylphenylboronic acid".

[0299] That 1 The H NMR data are as follows:

[0300] 1 H NMR(500MHz,DMSO-d6)δ8.69(s,1H),8.07(d,J=8.5Hz,2H),7.61(d,J=8.6Hz,2H), 7.37(dd,J=8.9,3.1Hz,1H),7.31(dd,J=8.4,3.1Hz,1H),4.65(s,2H),2.63(s,3H).

[0301] Embodiment 42:

[0302] The compound disclosed in this example: 8-(4-(methylsulfonyl)phenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-241)

[0303]

[0304] The synthetic route is the same as in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-(methylsulfonyl)phenylboronic acid".

[0305] That 1 The H NMR data are as follows:

[0306] 1 H NMR (500MHz, DMSO-d6) δ8.05(d,J=8.7Hz,2H),7.73(d,J=8.5Hz,2H),7.35(dd,J=8.9,3.1Hz,1H),7.27(dd,J=8.5,3.1Hz,1H),4.60(s,2H),3.30(s,3H).

[0307] Embodiment 43:

[0308] The compound disclosed in this example: 8-(3-methoxyphenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (LT-242)

[0309]

[0310] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "3-methoxyphenylboronic acid".

[0311] That 1 The H NMR data are as follows:

[0312] 1 H NMR (500MHz, DMSO-d6) δ8.64(s,1H),7.41(t,J=8.0Hz,1H),7.32(dd,J=9.0,3.1Hz,1H),7.25(d d,J=8.4,3.1Hz,1H),7.04–7.00(m,2H),6.99(dd,J=2.6,1.4Hz,1H),4.62(s,2H),3.80(s,3H).

[0313] Embodiment 44:

[0314] The compound disclosed in this example: 8-(4-trifluoromethoxyphenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-243)

[0315]

[0316] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-trifluoromethoxyphenylboronic acid".

[0317] That 1 The H NMR data are as follows:

[0318] 1 H NMR (500MHz, DMSO-d6) δ8.68(s,1H),7.63–7.57(m,2H),7.55–7.49(m,2H),7.37(dd,J=9.0,3.2Hz,1H),7.29(dd,J=8.5,3.1Hz,1H),4.65(s,2H).

[0319] Embodiment 45:

[0320] The compound disclosed in this example: 8-(2-methoxyphenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-244)

[0321]

[0322] The synthetic route is the same as in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "2-methoxyphenylboronic acid".

[0323] That 1 The H NMR data are as follows:

[0324] 1 H NMR(500MHz,DMSO-d6)δ8.51(s,1H),7.42(ddd,J=8.3,7.4,1.8Hz,1H),7.26–7.19(m ,1H),7.18–7.11(m,3H),7.04(td,J=7.4,1.0Hz,1H),4.64–4.56(m,2H),3.73(s,3H).

[0325] Embodiment 46:

[0326] The compound disclosed in this example: 8-(3-fluoro-4-methoxyphenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-245)

[0327]

[0328] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "3-fluoro-4-methoxyphenylboronic acid".

[0329] That 1 The H NMR data are as follows:

[0330] 1 H NMR (500MHz, DMSO-d6) δ7.34(dd,J=12.9,1.9Hz,1H),7.31–7.25(m,3H),7.19(dd,J=8.3,3.3Hz,1H),4.58(s,2H),3.90(s,3H).

[0331] Embodiment 47:

[0332] The compound disclosed in this example: 8-(2,3-dihydrobenzo[b][1,4]dioxane-6-yl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (LT-246)

[0333]

[0334] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "benzo-1,4-dioxane-6-boronic acid".

[0335] That 1 The H NMR data are as follows:

[0336] 1 H NMR (500MHz, DMSO-d6) δ8.60(s,1H),7.24(dd,J=9.1,3.1Hz,1H),7.20(dd,J=8.4,3.2Hz,1H),6. 98(d,J=8.2Hz,1H),6.96(d,J=2.1Hz,1H),6.93(dd,J=8.4,2.1Hz,1H),4.61(s,2H),4.30(s,4H).

[0337] Embodiment 48:

[0338] The compound disclosed in this example: 6-fluoro-8-(4-(naphthalen-1-yl)phenyl)-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-247)

[0339]

[0340] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-(1-naphthyl)phenylboronic acid".

[0341] That 1 The H NMR data are as follows:

[0342] 1 H NMR(600MHz, DMSO-d6)δ8.71(s,1H),8.04(dd,J=8.0,1.8Hz,1H),8.00(d,J=8.3Hz,1H),7.91–7.8 5(m,1H),7.69–7.48(m,8H),7.43(dd,J=8.9,3.2Hz,1H),7.30(dd,J=8.4,3.1Hz,1H),4.68(s,2H).

[0343] Embodiment 49:

[0344] The compound disclosed in this example: 8-([1,1'-biphenyl]-3-yl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-248)

[0345]

[0346] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "3-biphenylboronic acid".

[0347] That 1 The H NMR data are as follows:

[0348] 1 H NMR(600MHz,DMSO-d6)δ8.68(s,1H),7.77–7.69(m,4H),7.60(t,J=7.7Hz,1H),7.50(t,J=7 .7Hz,2H),7.47–7.43(m,2H),7.42–7.38(m,1H),7.28(dd,J=8.4,3.2Hz,1H),4.65(s,2H).

[0349] Embodiment 50:

[0350] The compound disclosed in this example: 8-(3-cyanophenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (LT-249)

[0351]

[0352] The synthetic route is the same as in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "3-cyanophenylboronic acid".

[0353] That 1 The H NMR data are as follows:

[0354] 1H NMR(600MHz,DMSO-d6)δ8.72(s,1H),7.96–7.91(m,2H),7.82–7.78(m,1H),7.73(t, J=7.8Hz,1H),7.43(dd,J=8.9,3.1Hz,1H),7.32(dd,J=8.4,3.1Hz,1H),4.65(s,2H).

[0355] Embodiment 51:

[0356] The compound disclosed in this example: 1-(3-(6-fluoro-2,2-dihydroxy-3,4-dihydrobenzo[e][1,2,3]oxathiazin-8-yl)phenyl)ethane-1-one (LT-250)

[0357]

[0358] The synthetic route is the same as in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "3-acetylphenylboronic acid".

[0359] That 1 The H NMR data are as follows:

[0360] 1 H NMR (600MHz, DMSO-d6) δ8.71–8.55(m,1H),7.88(dd,J=7.7,1.5Hz,1H),7.65(td,J=7.5,1.5Hz,1H),7. 58(td,J=7.6,1.4Hz,1H),7.32(dd,J=7.6,1.4Hz,1H),7.21(d,J=8.6Hz,2H),4.58(s,2H),2.45(s,3H).

[0361] Embodiment 52:

[0362] The compound disclosed in this example: methyl 3-(6-fluoro-2,2-dihydroxy-3,4-dihydrobenzo[e][1,2,3]oxathiazin-8-yl)benzoate (LT-251)

[0363]

[0364] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "3-methoxycarbonylphenylboronic acid".

[0365] That 1 The H NMR data are as follows:

[0366] 1H NMR (500MHz, DMSO-d6) δ8.68 (s, 1H), 8.11–7.95 (m, 2H), 7.72 (dt, J = 7.6, 1.4Hz, 1H), 7.68–7. 62(m,1H),7.37(dd,J=8.9,3.1Hz,1H),7.28(dd,J=8.4,3.1Hz,1H),4.63(s,2H),3.87(s,3H).

[0367] Embodiment 53:

[0368] The compound disclosed in this example: methyl 2-(6-fluoro-2,2-dihydroxy-3,4-dihydrobenzo[e][1,2,3]oxathiazin-8-yl)benzoate (LT-252)

[0369]

[0370] The synthetic route is the same as that in Example 20, except that the "4-toluene boronic acid" in step (4) is replaced by "2-methoxycarbonylphenylboronic acid".

[0371] That 1 The H NMR data are as follows:

[0372] 1 H NMR (500MHz, DMSO-d6) δ8.54(s,1H),7.88(dd,J=7.8,1.5Hz,1H),7.68(td,J=7.5,1.4Hz,1H),7.56( td,J=7.6,1.4Hz,1H),7.33(dd,J=7.7,1.3Hz,1H),7.21(d,J=8.9Hz,2H),4.57(s,2H),3.64(s,3H).

[0373] Embodiment 54:

[0374] The compound disclosed in this example: 8-(2-trifluoromethoxyphenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-253)

[0375]

[0376] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "2-trifluoromethoxyphenylboronic acid".

[0377] That 1 The H NMR data are as follows:

[0378] 1H NMR (500MHz, DMSO-d6) δ8.62(t,J=7.3Hz,1H),7.86(dd,J=7.9,1.5Hz,1H),7.75(td,J=7.6,1.4Hz,1H),7.71–7.65( m,1H),7.33(d,J=6.9Hz,1H),7.30(dd,J=8.6,3.1Hz,1H),7.20(dd,J=8.5,3.2Hz,1H),4.62(dd,J=7.2,3.2Hz,2H).

[0379] Embodiment 55:

[0380] This example discloses the compound: ethyl 3-(6-fluoro-2,2-dihydroxy-3,4-dihydrobenzo[e][1,2,3]oxathiazin-8-yl)benzoate (LT-254)

[0381]

[0382] The synthetic route is the same as that in Example 20, except that the "4-toluene boronic acid" in step (4) is replaced by "3-ethoxycarbonylphenylboronic acid".

[0383] That 1 The H NMR data are as follows:

[0384] 1 H NMR (500MHz, DMSO-d6) δ8.87–8.54(m,1H),8.09–7.95(m,2H),7.72(dt,J=7.8,1.5Hz,1H),7.68–7.60(m,1H),7.37(d d,J=8.9,3.2Hz,1H),7.28(dd,J=8.5,3.1Hz,1H),4.63(d,J=7.2Hz,2H),4.33(q,J=7.2Hz,2H),1.31(t,J=7.1Hz,3H).

[0385] Embodiment 56:

[0386] The compound disclosed in this example: 8-(2,3-dichlorophenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-255)

[0387]

[0388] The synthetic route is the same as in Example 20, except that "4-tolueneboric acid" in step (4) is replaced by "2,3-dichlorophenylboric acid".

[0389] That 1 The H NMR data are as follows:

[0390] 1 H NMR (500MHz, DMSO-d6) δ8.73–8.64 (m, 1H), 7.76 (dd, J=8.1, 1.5Hz, 1H), 7.49 (t, J= 7.9Hz,1H),7.38–7.33(m,2H),7.30(dd,J=8.5,3.1Hz,1H),4.65(d,J=3.8Hz,2H).

[0391] Embodiment 57:

[0392] The compound disclosed in this example: 8-(6-methoxypyridin-3-yl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-256)

[0393]

[0394] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "2-methoxy-5-pyridineboronic acid".

[0395] That 1 The H NMR data are as follows:

[0396] 1 H NMR (500MHz, DMSO-d6) δ8.67(s,1H),8.25(dd,J=2.6,0.9Hz,1H),7.78(dd,J=8.6,2.5Hz,1H),7.36(dd ,J=9.0,3.2Hz,1H),7.24(dd,J=8.5,3.1Hz,1H),6.95(dd,J=8.5,0.9Hz,1H),4.61(s,2H),3.89(s,3H).

[0397] Embodiment 58:

[0398] The compound disclosed in this example is: 8-(3-vinylphenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (LT-257)

[0399]

[0400] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "3-vinylbenzeneboronic acid".

[0401] That 1 The H NMR data are as follows:

[0402] 1H NMR(500MHz,DMSO-d6)δ8.64(s,1H),7.58–7.50(m,2H),7.46(t,J=7.6Hz,1H),7.38–7.30(m,2H),7.25(dd,J=8.5, 3.1Hz, 1H), 6.78 (dd, J=17.7, 11.0Hz, 1H), 5.89 (dd, J=17.7, 1.1Hz, 1H), 5.32 (dd, J=10.8, 1.1Hz, 1H), 4.62 (s, 2H).

[0403] Embodiment 59:

[0404] The compound disclosed in this example: 8-(2-methyl-2H-indazol-6-yl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-258)

[0405]

[0406] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "2-methyl-2H-indazole-6-boronic acid".

[0407] That 1 The H NMR data are as follows:

[0408] 1 H NMR (500MHz, DMSO-d6) δ8.60(s,1H),8.44(s,1H),7.77(dd,J=1.8,1.0Hz,1H),7.66(dt,J=9.0,1.0Hz,1H),7. 30(dd,J=9.1,3.1Hz,1H),7.27(dd,J=8.9,1.8Hz,1H),7.21(dd,J=8.5,3.1Hz,1H),4.62(s,2H),4.18(s,3H).

[0409] Embodiment 60:

[0410] The compound disclosed in this example: 8-(2-methoxypyridin-4-yl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-259)

[0411]

[0412] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "2-methoxypyridine-4-boronic acid".

[0413] That 1 The H NMR data are as follows:

[0414] 1 H NMR (600MHz, DMSO-d6) δ8.68(s,1H),8.25(d,J=5.3Hz,1H),7.37(dd,J=8.8,3.1Hz,1H),7.30(dd ,J=8.5,3.2Hz,1H),7.04(dd,J=5.2,1.6Hz,1H),6.86(d,J=1.9Hz,1H),4.61(s,2H),3.87(s,3H).

[0415] Example 61:

[0416] The compound disclosed in this example: 8-(1H-indol-4-yl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-260)

[0417]

[0418] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "indole-4-boric acid".

[0419] That 1 The H NMR data are as follows:

[0420] 1 H NMR (600MHz, DMSO-d6) δ11.26(s,1H),8.50(s,1H),7.45(d,J=8.1Hz,1H),7.37(t,J=2.8Hz,1H) ,7.22(d,J=9.0Hz,2H),7.16(t,J=7.7Hz,1H),6.94(d,J=7.2Hz,1H),6.23(s,1H),4.63(s,2H).

[0421] Embodiment 62:

[0422] The compound disclosed in this example: 8-(4-dimethylaminophenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-261)

[0423]

[0424] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-dimethylaminophenylboronic acid".

[0425] That 1 The H NMR data are as follows:

[0426] 1H NMR(500MHz,DMSO-d6)δ8.53(s,1H),7.30(d,J=8.8Hz,2H),7.18(dd,J=9.3,3.2Hz ,1H),7.10(dd,J=8.4,3.1Hz,1H),6.79(d,J=9.0Hz,2H),4.57(s,2H),2.94(s,6H).

[0427] Embodiment 63:

[0428] The compound disclosed in this example: 8-(6-aminopyridin-3-yl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-262)

[0429]

[0430] The synthetic route is the same as in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "6-aminopyridineboronic acid".

[0431] That 1 The H NMR data are as follows:

[0432] 1 H NMR (500MHz, DMSO-d6) δ8.57(s,1H),8.00(d,J=2.5Hz,1H),7.46(dd,J=8.7,2.5Hz,1H),7.23(dd ,J=9.1,3.2Hz,1H),7.13(dd,J=8.4,3.1Hz,1H),6.51(d,J=8.7Hz,1H),6.20(s,2H),4.58(s,2H).

[0433] Embodiment 64:

[0434] The compound disclosed in this example: 8-(6-morpholinylpyridin-3-yl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (LT-263)

[0435]

[0436] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "6-(4-morpholinyl)-3-pyridineboronic acid".

[0437] That 1 The H NMR data are as follows:

[0438] 1H NMR (500MHz, DMSO-d6) δ8.62(s,1H),8.24(d,J=2.5Hz,1H),7.67(dd,J=8.8,2.5Hz,1H),7.31(dd,J=9.1,3.2Hz,1H),7. 19(dd,J=8.4,3.2Hz,1H),6.95(d,J=9.0Hz,1H),4.61(s,2H),3.71(dd,J=5.8,4.1Hz,4H),3.53(dd,J=5.8,4.2Hz,4H).

[0439] Embodiment 65:

[0440] The compound disclosed in this example: 6-(6-fluoro-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-8-yl)-2H-1,4-benzoxazin-3(4H)-one (LT-264)

[0441]

[0442] The synthetic route is the same as that in Example 20, except that the "4-tolueneboronic acid" in step (4) is replaced by "(3-oxo-3,4-dihydro-2H-benzo[B][1,4]oxazin-6-yl)boronic acid".

[0443] That 1 The H NMR data are as follows:

[0444] 1 H NMR(500MHz,DMSO-d6)δ10.84(s,1H),8.69–8.50(m,1H),7.20(d,J=8.8Hz,2H) ,7.05(d,J=8.0Hz,1H),6.99–6.94(m,2H),4.62(s,2H),4.60(d,J=6.8Hz,2H).

[0445] Embodiment 66:

[0446] The compound disclosed in this example: 8-(3-methoxypyridin-4-yl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-265)

[0447]

[0448] The synthetic route is the same as in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "3-methoxypyridine-4-boronic acid".

[0449] That 1 The H NMR data are as follows:

[0450] 1 H NMR (500MHz, DMSO-d6) δ8.58(s,1H),8.51(s,1H),8.31(d,J=4.7Hz,1H),7.29(dd,J=8.5,3.2Hz,1H),7.26–7.22(m,2H),4.62(s,2H),3.87(s,3H).

[0451] Embodiment 67:

[0452] The compound disclosed in this example: 4-(6-fluoro-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-8-yl)-N,N-dimethylbenzamide (LT-266)

[0453]

[0454] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-(N,N-dimethylaminoformyl)phenylboronic acid".

[0455] That 1 The H NMR data are as follows:

[0456] 1 H NMR (500MHz, DMSO-d6) δ8.46(s,1H),7.51(s,4H),7.32(dd,J=8.9,3.2Hz,1H),7.25(dd,J=8.4,3.2Hz,1H),4.61(s,2H),2.99(s,3H),2.95(s,3H).

[0457] Embodiment 68:

[0458] The compound disclosed in this example: 8-(4-tert-butoxyphenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-267)

[0459]

[0460] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-tert-butoxyphenylboronic acid".

[0461] That 1 The H NMR data are as follows:

[0462] 1H NMR(500MHz,DMSO-d6)δ8.60(s,1H),7.39(d,J=8.7Hz,2H),7.27(dd,J=9.1,3.2Hz ,1H),7.21(dd,J=8.5,3.2Hz,1H),7.09(d,J=8.7Hz,2H),4.62(s,2H),1.36(s,9H).

[0463] Embodiment 69:

[0464] The compound disclosed in this example: 8-(3-isopropoxyphenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-268)

[0465]

[0466] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "3-isopropoxyphenylboronic acid".

[0467] That 1 The H NMR data are as follows:

[0468] 1 H NMR (500MHz, DMSO-d6) δ8.65–8.54(m,1H),7.37(t,J=7.9Hz,1H),7.28(dd,J=9.1,3.2Hz,1H ),7.22(dd,J=8.4,3.1Hz,1H),7.02–6.91(m,3H),4.70–4.53(m,3H),1.28(d,J=6.0Hz,6H).

[0469] Embodiment 70:

[0470] The compound disclosed in this example: 8-(2-isopropoxyphenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (LT-269)

[0471]

[0472] The synthetic route is the same as in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "2-isopropoxyphenylboronic acid".

[0473] That 1 The H NMR data are as follows:

[0474] 1H NMR(500MHz,DMSO-d6)δ8.42(t,J=7.3Hz,1H),7.36(ddd,J=9.0,7.3,1.8Hz,1H),7.18(dd,J=8.5,3.2Hz,1H),7.1 2(dd,J=7.5,1.8Hz,1H),7.10–7.06(m,2H),6.97(td,J=7.4,1.1Hz,1H),4.65–4.54(m,3H),1.18(d,J=6.1Hz,6H).

[0475] Embodiment 71:

[0476] The compound disclosed in this example: 3-(6-fluoro-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-8-yl)benzamide (LT-270)

[0477]

[0478] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "3-carbamoylphenylboronic acid".

[0479] That 1 The H NMR data are as follows:

[0480] 1 H NMR(500MHz,DMSO-d6)δ8.60(s,1H),8.04(s,1H),7.95–7.87(m,2H),7.63–7.51(m,2H) ),7.42(s,1H),7.35(dd,J=9.0,3.2Hz,1H),7.26(dd,J=8.4,3.2Hz,1H),4.62(s,2H).

[0481] Embodiment 72:

[0482] The compound disclosed in this example: 4-(6-fluoro-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-8-yl)-N-methylbenzamide (LT-271)

[0483]

[0484] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-(N-methylaminoformyl)phenylboronic acid".

[0485] That 1 The H NMR data are as follows:

[0486] 1H NMR(500MHz,DMSO-d6)δ8.50(q,J=4.7Hz,2H),7.91(d,J=8.4Hz,2H),7.52(d,J=8.4Hz,2H), 7.32(dd,J=8.9,3.2Hz,1H),7.25(dd,J=8.5,3.2Hz,1H),4.61(s,2H),2.79(d,J=4.6Hz,3H).

[0487] Embodiment 73:

[0488] The compound disclosed in this example: 5-(6-fluoro-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-8-yl)isoindol-1-one (LT-272)

[0489]

[0490] The synthetic route is the same as that in Example 20, except that the "4-toluene boronic acid" in step (4) is replaced by "1-isoindolone-5-boric acid pinacol ester".

[0491] That 1 The H NMR data are as follows:

[0492] 1 H NMR (500MHz, DMSO-d6) δ8.61(s,1H),7.75(d,J=7.9Hz,1H),7.62(s,1H),7.52(dd,J=7.8,1. 7Hz,1H),7.27(dd,J=9.0,3.2Hz,1H),7.22(dd,J=8.4,3.2Hz,1H),4.57(s,2H),4.42(s,2H).

[0493] Embodiment 74:

[0494] The compound disclosed in this example: 4-(6-fluoro-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-8-yl)-N-isopropylbenzamide (LT-273)

[0495]

[0496] The synthetic route is the same as that in Example 20, except that the "4-tolueneboronic acid" in step (4) is replaced by "4-(N-isopropylaminocarbonyl)phenylboronic acid".

[0497] That 1 The H NMR data are as follows:

[0498] 1H NMR (500MHz, DMSO-d6) δ8.62(s,1H),8.28(d,J=7.7Hz,1H),7.91(d,J=8.5Hz,2H),7.51(d,J=8.4Hz,2H),7.3 3(dd,J=8.8,3.2Hz,1H),7.27(dd,J=8.4,3.2Hz,1H),4.62(s,2H),4.16–4.02(m,1H),1.16(d,J=6.5Hz,6H).

[0499] Embodiment 75:

[0500] This example discloses the compound 4-(6-fluoro-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-8-yl)-N-phenylacylpiperidine (LT-274)

[0501]

[0502] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-(piperidine-1-carbonyl)phenylboronic acid".

[0503] That 1 The H NMR data are as follows:

[0504] 1 H NMR (600MHz, DMSO-d6) δ8.63(s,1H),7.49(d,J=8.4Hz,2H),7.46(d,J=8.4Hz,2H),7.32(dd,J=8.9,3.1Hz,1H),7.24(dd,J=8 .3,3.1Hz,1H),4.61(s,2H),3.61–3.52(m,2H),3.29–3.24(m,2H),1.65–1.57(m,2H),1.56–1.51(m,2H),1.49–1.43(m,2H).

[0505] Embodiment 76:

[0506] The compound disclosed in this example: (4-(6-fluoro-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-8-yl)phenyl)(phenyl)methanone (LT-275)

[0507]

[0508] The synthetic route is the same as in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-benzoylphenylboronic acid".

[0509] That 1 The H NMR data are as follows:

[0510] 1 H NMR(600MHz,DMSO-d6)δ8.67(s,1H),7.83(d,J=8.4Hz,2H),7.79–7.74(m,2H),7.71–7.65(m,1H),7.63(d, J=8.3Hz,2H),7.57(t,J=7.8Hz,2H),7.37(dd,J=8.8,3.2Hz,1H),7.29(dd,J=8.4,3.1Hz,1H),4.63(s,2H).

[0511] Embodiment 77:

[0512] The compound disclosed in this example: (4-(6-fluoro-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-8-yl)phenyl)(pyrrolidine-1-yl)methanone (LT-276)

[0513]

[0514] The synthetic route is the same as that in Example 20, except that the "4-tolueneboronic acid" in step (4) is replaced by "4-pyrrololinylcarbonylphenylboronic acid".

[0515] That 1 The H NMR data are as follows:

[0516] 1 H NMR (500MHz, DMSO-d6) δ8.67(s,1H),7.65(d,J=8.4Hz,2H),7.53(d,J=8.4Hz,2H),7.35(dd,J=9.0,3.2Hz,1H),7.29(d d,J=8.4,3.2Hz,1H),4.65(s,2H),3.50(t,J=6.9Hz,2H),3.45(t,J=6.5Hz,2H),1.95–1.87(m,2H),1.86–1.79(m,2H).

[0517] Embodiment 78:

[0518] The compound disclosed in this example: N,N-diethyl-4-(6-fluoro-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-8-yl)benzamide (LT-277)

[0519]

[0520] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-(N,N-diethylcarbamoyl)phenylboronic acid".

[0521] That 1 The H NMR data are as follows:

[0522] 1 H NMR (600MHz, DMSO-d6) δ8.63(s,1H),7.49(d,J=8.2Hz,2H),7.44(d,J=8.2Hz,2H),7.32(dd,J=8.9,3.3Hz,1H),7.2 4(dd,J=8.4,3.3Hz,1H),4.61(s,2H),3.48–3.38(m,2H),3.26–3.14(m,2H),1.18–1.10(m,3H),1.09–1.00(m,3H).

[0523] Embodiment 79:

[0524] The compound disclosed in this example: (4-(6-fluoro-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-8-yl)phenyl)(morpholinyl)methanone (LT-278)

[0525]

[0526] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-(morpholine-4-carbonyl)phenylboronic acid".

[0527] That 1 The H NMR data are as follows:

[0528] 1 H NMR (600MHz, DMSO-d6) δ7.70–7.39(m,4H),7.30(dd,J=8.9,3.2Hz,1H),7.24(dd,J=8.4,3.2Hz,1H),4.60(s,2H),3.75–3.49(m,8H).

[0529] Embodiment 80:

[0530] The compound disclosed in this example: 4-(6-fluoro-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-8-yl)benzamide (LT-279)

[0531]

[0532] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-carbamoylphenylboronic acid".

[0533] That 1 The H NMR data are as follows:

[0534] 1 H NMR (600MHz, DMSO-d6) δ8.63(s,1H),8.03(s,1H),7.94(d,J=8.4Hz,2H),7.50(d,J=8.3Hz ,2H),7.42(s,1H),7.32(dd,J=8.8,3.1Hz,1H),7.25(dd,J=8.4,3.2Hz,1H),4.61(s,2H).

[0535] Embodiment 81:

[0536] The compound disclosed in this example: 8-(4-ethoxyphenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-280)

[0537]

[0538] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-ethoxyphenylboronic acid".

[0539] That 1 The H NMR data are as follows:

[0540] 1 H NMR (500MHz, DMSO-d6) δ8.57(s,1H),7.37(d,J=8.8Hz,2H),7.23(dd,J=9.1,3.2Hz,1H),7.17(dd,J =8.4, 3.2Hz, 1H), 7.02 (d, J = 8.8Hz, 2H), 4.59 (s, 2H), 4.07 (q, J = 6.9Hz, 2H), 1.33 (t, J = 6.9Hz, 3H).

[0541] Embodiment 82:

[0542] The compound disclosed in this example: 6-(6-fluoro-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-8-yl)isoindol-1-one (LT-281)

[0543]

[0544] The synthetic route is the same as that in Example 20, except that the "4-toluene boronic acid" in step (4) is replaced by "1-isoindolone-6-boronic acid pinacol ester".

[0545] That 1 The H NMR data are as follows:

[0546] 1H NMR(500MHz,DMSO-d6)δ8.65(s,1H),8.62(s,1H),7.71–7.67(m,2H),7.64(dd,J=8.0,1.7H z,1H),7.35(dd,J=8.8,3.2Hz,1H),7.26(dd,J=8.4,3.1Hz,1H),4.62(s,2H),4.42(s,2H).

[0547] Embodiment 83:

[0548] The compound disclosed in this example: 8-(4-cyclopropylphenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-282)

[0549]

[0550] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-cyclopropylphenylboronic acid".

[0551] That 1 The H NMR data are as follows:

[0552] 1 H NMR(500MHz,DMSO-d6)δ8.58(s,1H),7.32(d,J=8.2Hz,2H),7.23(dd,J=9.1,3.2Hz,1H),7.21 –7.16(m,3H),4.60(s,2H),1.95(tt,J=8.4,5.0Hz,1H),1.01–0.92(m,2H),0.75–0.68(m,2H).

[0553] Embodiment 84:

[0554] The compound disclosed in this example: 8-(4-isobutylphenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (LT-283)

[0555]

[0556] The synthetic route is the same as in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-isobutylphenylboronic acid".

[0557] That 1 The H NMR data are as follows:

[0558] 1H NMR(500MHz,DMSO-d6)δ8.60(s,1H),7.38(d,J=8.2Hz,2H),7.31–7.26(m,3H),7.22(dd,J=8.4 ,3.2Hz,1H),4.62(s,2H),2.53–2.50(m,2H),1.89(hept,J=6.8Hz,1H),0.90(d,J=6.6Hz,6H).

[0559] Embodiment 85:

[0560] The compound disclosed in this example: 4-(6-fluoro-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-8-yl)(phenyl)(4-methyl-1-piperazinyl)methanone (LT-284)

[0561]

[0562] The synthetic route is the same as that in Example 20, except that the "4-tolueneboronic acid" in step (4) is replaced by "4-(4-methyl-1-piperazinyl)phenylboronic acid".

[0563] That 1 The H NMR data are as follows:

[0564] 1 H NMR(400MHz, DMSO-d6)δ8.70(s,1H),7.60–7.46(m,4H),7.36(dd,J=8.9,3.2Hz,1H),7.28(dd,J=8 .4,3.2Hz,1H),4.65(s,2H),3.72–3.59(m,2H),3.44–3.31(m,2H),2.43–2.27(m,4H),2.21(s,3H).

[0565] Embodiment 86:

[0566] The compound disclosed in this example: 8-(4-(piperidin-1-yl)phenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-285)

[0567]

[0568] The synthetic route is the same as that in Example 20, except that the "4-tolueneboronic acid" in step (4) is replaced by "4-piperidinylphenylboronic acid hydrochloride".

[0569] That 1 The H NMR data are as follows:

[0570] 1H NMR (400MHz, DMSO-d6) δ8.58(s,1H),7.32(d,J=8.8Hz,2H),7.22(dd,J=9.3,3.2Hz,1H),7.15(dd ,J=8.4,3.1Hz,1H),7.02(d,J=9.0Hz,2H),4.60(s,2H),3.24(t,J=5.3Hz,4H),1.69–1.50(m,6H).

[0571] Embodiment 87:

[0572] The compound disclosed in this example: 8-(4-(diethylamino)phenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-286)

[0573]

[0574] The synthetic route is the same as in Example 20, except that the "4-tolueneboronic acid" in step (4) is replaced by "4-(diethylamino)phenylboronic acid".

[0575] That 1 The H NMR data are as follows:

[0576] 1 H NMR (400MHz, DMSO-d6) δ8.57(s,1H),7.30(d,J=8.8Hz,2H),7.19(dd,J=9.4,3.3Hz,1H),7.11(dd,J =8.3, 3.4Hz, 1H), 6.75 (d, J = 8.9Hz, 2H), 4.59 (s, 2H), 3.39 (q, J = 7.0Hz, 4H), 1.12 (t, J = 7.0Hz, 6H).

[0577] Embodiment 88:

[0578] The compound disclosed in this example is: 8-(4-(cyclohexyloxy)phenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-287)

[0579]

[0580] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "(4-cyclohexyloxy)phenylboronic acid".

[0581] That 1 The H NMR data are as follows:

[0582] 1H NMR (400MHz, DMSO-d6) δ8.61(t,J=7.0Hz,1H),7.38(d,J=7.3Hz,2H),7.25(dd,J=9.2,4.0Hz,1H),7.19(dd,J=8.6,3.9Hz,1H),7.05(d,J=7 .6Hz,2H),4.62(d,J=7.0Hz,2H),4.42(dq,J=8.8,4.6Hz,1H),2.02–1.88(m,2H),1.80–1.68(m,2H),1.40(tdt,J=47.0,22.1,11.6Hz,6H).

[0583] Embodiment 89:

[0584] The compound disclosed in this example: 8-(4-(4-methylpiperazin-1-yl)phenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-288)

[0585]

[0586] The synthetic route is the same as that in Example 20, except that the "4-tolueneboronic acid" in step (4) is replaced by "4-(4-methyl-1-piperazinyl)phenylboronic acid".

[0587] That 1 The H NMR data are as follows:

[0588] 1 H NMR (400MHz, DMSO-d6) δ7.34(d,J=8.6Hz,2H),7.23(dd,J=9.2,3.4Hz,1H),7.16(dd,J=8.4,3.2 Hz,1H),7.05(d,J=8.8Hz,2H),4.60(s,2H),3.40–3.30(m,4H),2.60–2.53(m,4H),2.29(s,3H).

[0589] Embodiment 90:

[0590] The compound disclosed in this example: 8-(4-morpholinophenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide (LT-289)

[0591]

[0592] The synthetic route is the same as in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-morpholinephenylboronic acid".

[0593] That 1 The H NMR data are as follows:

[0594] 1 H NMR (400MHz, DMSO-d6) δ8.59(s,1H),7.36(d,J=7.7Hz,2H),7.24(dd,J=9.2,4.0Hz,1H),7.16(dd,J =8.3, 3.7Hz, 1H), 7.05 (d, J = 8.1Hz, 2H), 4.61 (s, 2H), 3.76 (t, J = 5.1Hz, 4H), 3.19 (t, J = 5.2Hz, 4H).

[0595] Embodiment 91:

[0596] The compound disclosed in this example: 8-(4-(pyrrolidin-1-yl)phenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-290)

[0597]

[0598] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-pyrrolidinophenylborate hydrochloride".

[0599] That 1 The H NMR data are as follows:

[0600] 1 H NMR (400MHz, DMSO-d6) δ8.50(s,1H),7.31(d,J=8.1Hz,2H),7.19(dd,J=9.5,3.0Hz,1H),7.11(dd,J =8.4,3.4Hz,1H),6.63(d,J=8.6Hz,2H),4.59(s,2H),3.27(d,J=6.6Hz,4H),1.99(d,J=6.6Hz,4H).

[0601] Embodiment 92:

[0602] The compound disclosed in this example: 8-(4-propoxyphenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-291)

[0603]

[0604] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-propoxyphenylboronic acid".

[0605] That 1 The H NMR data are as follows:

[0606] 1 H NMR (400MHz, DMSO-d6) δ8.62(s,1H),7.40(d,J=8.7Hz,2H),7.25(dd,J=9.2,3.3Hz,1H),7.20(dd,J=8.4,3.3H z,1H),7.05(d,J=8.7Hz,2H),4.62(s,2H),3.99(t,J=6.5Hz,2H),1.76(h,J=7.2Hz,2H),1.00(t,J=7.4Hz,3H).

[0607] Embodiment 93:

[0608] The compound disclosed in this example: 8-(4-(methoxymethoxy)phenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-292)

[0609]

[0610] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-(methoxymethoxy)phenylboronic acid".

[0611] That 1 The H NMR data are as follows:

[0612] 1 H NMR(400MHz,DMSO-d6)δ8.63(s,1H),7.41(d,J=7.3Hz,2H),7.27(dd,J=9.1,3.9Hz,1H),7 .21(dd,J=8.6,3.9Hz,1H),7.15(d,J=7.5Hz,2H),5.26(s,2H),4.62(s,2H),3.41(s,3H).

[0613] Embodiment 94:

[0614] The compound disclosed in this example: 8-(4-isobutoxyphenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-293)

[0615]

[0616] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-isobutoxyphenylboronic acid".

[0617] That 1 The H NMR data are as follows:

[0618] 1H NMR (400MHz, DMSO-d6) δ8.61(s,1H),7.40(d,J=8.6Hz,2H),7.25(dd,J=9.1,3.5Hz,1H),7.20(dd,J=8.4,3.7Hz, 1H), 7.06 (d, J = 8.7Hz, 2H), 4.62 (s, 2H), 3.81 (d, J = 6.6Hz, 2H), 2.04 (hept, J = 6.7Hz, 1H), 1.00 (d, J = 6.7Hz, 6H).

[0619] Embodiment 95:

[0620] The compound disclosed in this example: 8-(4-(morpholinomethyl)phenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-294)

[0621]

[0622] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-morpholinemethylphenylboronic acid".

[0623] That 1 The H NMR data are as follows:

[0624] 1 H NMR(400MHz, DMSO-d6)δ8.64(s,1H),7.47–7.38(m,4H),7.30(dd,J=9.0,3.2Hz,1H),7.24( dd,J=8.4,3.2Hz,1H),4.63(s,2H),3.60(t,J=4.7Hz,4H),3.52(s,2H),2.55–2.46(m,4H).

[0625] Embodiment 96:

[0626] The compound disclosed in this example: 8-(4-(2-methoxyethoxy)phenyl)-6-fluoro-3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide (LT-295)

[0627]

[0628] The synthetic route is the same as that in Example 20, except that "4-tolueneboronic acid" in step (4) is replaced by "4-(2-methoxyethoxy)phenylboronic acid".

[0629] That 1 The H NMR data are as follows:

[0630] 1H NMR(400MHz, DMSO-d6)δ8.61(s,1H),7.46–7.35(m,2H),7.26(dd,J=9.1,3.1Hz,1H),7.20(dd,J=8.4 ,3.2Hz,1H),7.07(d,J=8.8Hz,2H),4.62(s,2H),4.22–4.10(m,2H),3.74–3.64(m,2H),3.33(s,3H).

[0631] Embodiment 97:

[0632] The compound disclosed in this example: tert-butyloxy 4-(4-(6-fluoro-2,2-dioxido-3,4-dihydrobenzo[e][1,2,3]oxathiazin-8-yl)phenyl)piperazine-1-carboxylate (LT-296)

[0633]

[0634] The synthetic route is the same as that in Example 20, except that the "4-tolueneboronic acid" in step (4) is replaced by "4-(4-tert-butyloxycarbonylpiperazine)phenylboronic acid pinacol ester".

[0635] That 1 The H NMR data are as follows:

[0636] 1 H NMR (400MHz, DMSO-d6) δ8.59(s,1H),7.35(d,J=8.9Hz,2H),7.24(dd,J=9.2,3.2Hz,1H),7.16(dd,J=8.4, 3.1Hz, 1H), 7.06 (d, J = 8.9Hz, 2H), 4.61 (s, 2H), 3.48 (t, J = 5.3Hz, 4H), 3.21 (t, J = 5.2Hz, 4H), 1.43 (s, 9H).

[0637] Embodiment 98:

[0638] This example is based on the 97 compounds provided in the above examples, and biological activity tests are performed on them, as follows:

[0639] Preparation of primary neurons in rats: Neurons were obtained from 19-day-old SD rats. The embryos were placed in pre-cooled HBSS buffer. The fetal brain was removed under a microscope, the meninges were removed, the hippocampus was separated, and the brain tissue was cut into 1 mm pieces using iris scissors. 3 The cells were granulated into a paste, and DMEM containing 10% FBS was added to disperse the cells into a single cell suspension. 5 / mL was inoculated into a PDL-coated culture plate and placed in an incubator for culture. After 6 hours, the medium was changed and culture was continued with Neurobasal medium (2% B27 + 2mM glutamine), and the medium was changed every 2 days.

[0640] Ca 2+ Ca influx assay: Ca influx assay was performed after 5 days of primary neuron culture. 2+ Small molecule screening for influx. After aspirating the culture medium, add 100 μL Loading Buffer (3 μM fluorescent calcium indicator Fluo4-AM, 0.04% Pluronic F-127, 1.25 mM probenecid, 10 mM HEPES, 0.05% BSA, DMEM) to each well, and incubate the cells in an incubator for 50 minutes. Then aspirate the Loading Buffer, wash once with Recording Medium (1.25 mM probenecid, 10 mM HEPES, 0.05% BSA, DMEM), and add 100 μL Recording Medium to each well again. Use a fluorescent microplate reader to detect compound-induced intracellular Ca in the presence and absence of 5 μM s-AMPA. 2+ The relative increase of the level lasted for 15 minutes. The activity of the compound was defined as the fluorescence intensity integrated during the entire measurement period. The intensity of 0% was defined as the activity in the presence of only 5 μM s-AMPA, while the intensity of 100% was defined as the activity in the presence of 5 μM s-AMPA and 10 μM TAK-137. Activity (%) = (MA) / (NA), M: 1 μM of the test compound caused an increase in fluorescence after the addition of 5 μM s-AMPA; N: 10 μM of the positive compound TAK-137 caused an increase in fluorescence after the addition of 5 μM s-AMPA; A: The increase in fluorescence caused by the addition of only 5 μM s-AMPA.

[0641] The results of calcium influx test are shown in Table 1:

[0642] Table 1 Calcium influx test results of all compounds

[0643]

[0644]

[0645] According to the above table, compounds LT-261, LT-285, LT-286, LT-287 and LT-290 were selected for calcium influx EC50 test. 50 test.

[0646] Calculation of EC using logistic regression analysis 50The data are the average values ​​of 3 or more repeated experiments. GraphPad was used for data processing.

[0647] Specific results, such as Figures 1 to 5 The specific values ​​are shown in Table 2:

[0648] Table 2 Calcium influx EC of some compounds 50 test

[0649] Compound No. <![CDATA[EC 50 (nM)]]> <![CDATA[E max (%)]]> LT-261 168.8 126.1 LT-285 131.3 154.9 LT-286 812.1 173.1 LT-287 3016 204.0 LT-290 371.5 153.6

[0650] Experimental conclusion: The small molecule claimed in the present application can promote calcium ion influx in primary neurons in a dose-dependent manner and exhibit positive regulatory activity on AMPA receptors.

Claims

1. 6-substituted 3,4-dihydrobenzo[e][1,2,3]thiazine 2,2-dioxide compounds, including the following structure:

2. A positive allosteric modulator of AMPA receptor, characterized in that It is a biopharmaceutically acceptable salt of the 6-substituted 3,4-dihydrobenzo[e][1,2,3]oxathiazine 2,2-dioxide compound described in claim 1.

3. A drug for treating neuropsychiatric diseases, characterized in that: A pharmaceutical composition prepared with the positive allosteric modulator of the AMPA receptor as claimed in claim 2 as the main component, and a pharmaceutically acceptable, non-toxic and non-inert pharmaceutical carrier and / or excipient auxiliary component added.

4. The drug for treating neuropsychiatric diseases according to claim 3, characterized in that: The pharmaceutical carrier or excipient is one or more solid, semi-solid and liquid diluents, fillers and pharmaceutical product adjuvants.

5. The drug for treating neuropsychiatric diseases according to claim 3 or 4, characterized in that: The pharmaceutical composition is prepared into various dosage forms using methods recognized in the pharmaceutical and food fields: spray, aerosol, liquid preparation or solid preparation; the liquid preparation includes injection, suspension, emulsion, solution or syrup; the solid preparation includes tablets, capsules, granules or granules.

6. The drug for treating neuropsychiatric diseases according to claim 3 or 4, characterized in that: The neuropsychiatric diseases that can be treated by the drug include schizophrenia, Alzheimer's disease, Parkinson's disease, depression, and bipolar disorder.

7. The drug for treating neuropsychiatric diseases according to claim 3 or 4, characterized in that: The administration route of the drug includes oral administration, sublingual administration or mucosal dialysis; the injection route of the drug includes intravenous injection, intravenous drip, intramuscular injection, intraperitoneal injection or subcutaneous injection.